Skip to main content
Premium Trial:

Request an Annual Quote

Caprion Collaborating with FNIH on Alzheimer's Biomarkers

NEW YORK (GenomeWeb) – Caprion Biosciences said today it has entered a collaboration with the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium to measure protein biomarkers linked to early disease progression in Alzheimer's.

Under the collaboration, Caprion will use its ProteoCarta mass spec platform to measure the levels of five proteins in the cerebrospinal fluid of more than 200 subjects including patients with Alzheimer's disease, mild cognitive impairment, and healthy controls, with the goal of determining the ability of these proteins to track disease progression. Patients will be tracked over the course of three years or more.

The company will also measure an additional 140 CSF proteins that have been linked to Alzheimer's and other central nervous system diseases.

"This partnership with the FNIH is a great example of Caprion's ongoing commitment to identifying and validating biomarkers of CNS diseases," Martin LeBlanc, Caprion's CEO, said in a statement. "Our CNS ProteoCarta biomarker panel builds on Caprion's expertise in large targeted protein assays in multiple therapeutic areas including Alzheimer's, Parkinson's, and Huntington's diseases."

Project participants also include Genentech, Janssen, Lundbeck, Merck, Takeda, the University of Pennsylvania, and Yale School of Medicine.